Back to search
FDAFDA · Food and drugs·Recall number D-0995-2022

TobraDex (tobramycin and dexamethasone), Ophthalmic Ointment, 3.5 gm, Rx only, Manufacturer: Novartis, NDC 0078-0876-01

Published June 15, 2022 · Recall initiated: April 13, 2022

Summary

FDA records drug Class II recall D-0995-2022, published June 15, 2022 and initiated April 13, 2022. Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office; Status: Terminated; Reported quantity: 3 tubes; Lot: McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer. The letters clearly explain that consignees should identify product received from MMS between June 1 and September 30, 2021. A consignee should be able to use its own records to determine whether it received an impacted product from MMS during that timeframe and whether it still has any of that product in inventory. The recall notification letter informs consignees that they may contact Sedgwick if they have any questions. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations: Temperature abuse

What to do

Voluntary: Firm initiated · Letter

Get an email if TOBRADEX has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
TOBRADEX
Manufacturer
Mckesson Medical-Surgical Inc. Corporate Office
Distributor
USA nationwide.
Lot
McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer. The letters clearly explain that consignees should identify product received from MMS between June 1 and September 30, 2021. A consignee should be able to use its own records to determine whether it received an impacted product from MMS during that timeframe and whether it still has any of that product in inventory. The recall notification letter informs consignees that they may contact Sedgwick if they have any questions.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was TobraDex (tobramycin and dexamethasone), Ophthalmic Ointment, 3.5 gm, Rx only, Manufacturer: Novartis, NDC 0078-0876-01 recalled?

Yes. FDA published recall D-0995-2022 on June 15, 2022. Reported hazard: cGMP deviations: Temperature abuse

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: TOBRADEX.